Literature DB >> 35412513

Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome.

Sarah Ballou1, Julia W Haas, Johanna Iturrino, Judy Nee, Irving Kirsch, Vikram Rangan, Vivian Cheng, Anthony Lembo, Ted J Kaptchuk, John M Kelley.   

Abstract

OBJECTIVE: There is growing evidence that open-label placebo (OLP) may be an efficacious treatment of chronic and functional conditions. However, patient-level predictors of response to OLP have not been clearly identified. The aim of this study is to evaluate the psychological predictors of response to OLP and to compare this to double-blind placebo (DBP) and no-pill control (NPC).
METHODS: This study is a secondary analysis of data collected in a 6-week randomized controlled trial evaluating placebo effects in irritable bowel syndrome (IBS). The primary outcome was change in IBS severity. Hierarchical linear regression identified predictors of placebo response in general and compared them between those randomized to OLP, DBP, and NPC. Predictor variables included personality traits, generalized anxiety, depression, visceral sensitivity (a measure of symptom-specific anxiety), and pain catastrophizing.
RESULTS: A total of 210 participants (mean age = 42.3 years, 73.3% female) were included. Regression models revealed that visceral sensitivity was a predictor of response to OLP and NPC but not DBP. Interestingly, the effects were opposite, with high visceral sensitivity predicting less improvement in NPC and more improvement in OLP. Pain catastrophizing was a negative predictor of response to OLP (i.e., high pain catastrophizing was associated with less improvement in OLP). Neither visceral sensitivity nor pain catastrophizing played a significant role for response to DBP.
CONCLUSIONS: IBS participants who score low on the Pain Catastrophizing Scale but high on the Visceral Sensitivity Index seem to benefit particularly from OLP. Our study suggests that different psychological mechanisms may be involved in DBP and OLP interventions.
Copyright © 2022 by the American Psychosomatic Society.

Entities:  

Mesh:

Year:  2022        PMID: 35412513      PMCID: PMC9271597          DOI: 10.1097/PSY.0000000000001078

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   3.864


  40 in total

1.  Impact Of Irritable Bowel Syndrome With Constipation On Work Productivity And Daily Activity Among Commercially Insured Patients In The United States.

Authors:  J J Stephenson; J L Buono; W M Spalding; Q Cai; H Tan; R T Carson; J A Doshi
Journal:  Value Health       Date:  2014-10-26       Impact factor: 5.725

2.  Pain catastrophizing mediates the relationship between worry and pain suffering in patients with irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Brian M Quigley
Journal:  Behav Res Ther       Date:  2004-09-25

3.  Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms.

Authors:  Lene Vase; Michael E Robinson; G Nicholas Verne; Donald D Price
Journal:  Pain       Date:  2005-06       Impact factor: 6.961

Review 4.  Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome.

Authors:  M Delvaux
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

5.  Relieving patients' pain with expectation interventions: a meta-analysis.

Authors:  Kaya J Peerdeman; Antoinette I M van Laarhoven; Sascha M Keij; Lene Vase; Maroeska M Rovers; Madelon L Peters; Andrea W M Evers
Journal:  Pain       Date:  2016-06       Impact factor: 6.961

6.  Open-label placebo reduces fatigue in cancer survivors: a randomized trial.

Authors:  Eric S Zhou; Kathryn T Hall; Alexis L Michaud; Jaime E Blackmon; Ann H Partridge; Christopher J Recklitis
Journal:  Support Care Cancer       Date:  2018-10-10       Impact factor: 3.603

7.  Placebos without deception: a randomized controlled trial in irritable bowel syndrome.

Authors:  Ted J Kaptchuk; Elizabeth Friedlander; John M Kelley; M Norma Sanchez; Efi Kokkotou; Joyce P Singer; Magda Kowalczykowski; Franklin G Miller; Irving Kirsch; Anthony J Lembo
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

8.  Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.

Authors:  Anthony Lembo; John M Kelley; Judy Nee; Sarah Ballou; Johanna Iturrino; Vivian Cheng; Vikram Rangan; Jesse Katon; William Hirsch; Irving Kirsch; Kathryn Hall; Roger B Davis; Ted J Kaptchuk
Journal:  Pain       Date:  2021-09-01       Impact factor: 7.926

9.  Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial.

Authors:  Teri W Hoenemeyer; Ted J Kaptchuk; Tapan S Mehta; Kevin R Fontaine
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

10.  Open-label placebo treatment in chronic low back pain: a randomized controlled trial.

Authors:  Cláudia Carvalho; Joaquim Machado Caetano; Lidia Cunha; Paula Rebouta; Ted J Kaptchuk; Irving Kirsch
Journal:  Pain       Date:  2016-12       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.